GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (NAS:TMDX) » Definitions » 5-Year Yield-on-Cost %

TransMedics Group (TransMedics Group) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 04, 2024)


View and export this data going back to 2019. Start your Free Trial

What is TransMedics Group 5-Year Yield-on-Cost %?

TransMedics Group's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for TransMedics Group's 5-Year Yield-on-Cost % or its related term are showing as below:



TMDX's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.16
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of TransMedics Group's 5-Year Yield-on-Cost %

For the Medical Devices subindustry, TransMedics Group's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TransMedics Group's 5-Year Yield-on-Cost % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where TransMedics Group's 5-Year Yield-on-Cost % falls into.



TransMedics Group 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of TransMedics Group is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

TransMedics Group  (NAS:TMDX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


TransMedics Group 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of TransMedics Group's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


TransMedics Group (TransMedics Group) Business Description

Traded in Other Exchanges
Address
200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.
Executives
Tamer I Khayal officer: Chief Commercial Officer TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Miriam Provost officer: VP of US Regulatory & FDA Rel. 2000 MINUTEMAN ROAD, ANDOVER MA 01810
Waleed H Hassanein director, officer: President & CEO TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Stephen Gordon officer: Chief Financial Officer 200 MINUTEMAN ROAD, ANDOVER MA 01810
David Weill director 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Anil P. Ranganath officer: See Remarks C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Edward M Basile director 200 MINUTEMAN ROAD, ANDOVER MA 01810
John F Carey officer: VP of Operations 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Nicholas Corcoran officer: See Remarks C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Laura Damme officer: VP, Clinical Affairs C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephanie Lovell director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kania Edwin M Jr director
Rakesh P. Godhani officer: Chief Digital Officer C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
John F Sullivan officer: VP of Quality & Engineering 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810